Haematology and blood transfusion最新文献_第5页

Treatment of acute lymphoblastic leukemia: protocol Fralle 83-85. 急性淋巴细胞白血病的治疗:方案Fralle 83-85。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_84

Gérard Schaison, D. Olive, G. Leverger, J. Vannier, L. D. Lumley, A. Bancillon, Guy Cornu

引用次数: 8

Acute monocytic leukemia with translocation t(1;11) (p31;q23): simultaneous staining of chromosomes and cell surface antigens. 急性单核细胞白血病易位t(1;11) (p31;q23):染色体和细胞表面抗原同时染色。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_27

I Nölle, B Schlegelberger, N Schmitz, S Bödewadt-Radzun, W Grote

引用次数: 5

Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia. 中剂量Ara-C/m-AMSA用于缓解诱导，高剂量Ara-C/m-AMSA用于复发和难治性成人急性骨髓性白血病的强化巩固。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_63

U Jehn, V Heinemann

{"title":"Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.","authors":"U Jehn, V Heinemann","doi":"10.1007/978-3-642-74643-7_63","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_63","url":null,"abstract":"Thirty-four consecutive patients with either relapsed (n = 28) or primary refractory AML (n = 6) were treated with one or two cycles of intermediate-dose (ID) cytosine arabinoside (Ara-C) (1 g/m2 i.v. q 12 h days 1-6) and amsacrine (m-AMSA) (120 mg/m2 i.v. days 5-7). Patients reaching complete remission (CR) were consolidated with one cycle of Ara-C 3 g/m2 i.v. q 12 h days 1-4 and m-AMSA 120 mg/m2 i.v. day 5. The median duration of the preceding remission was 8 months and median time from last chemotherapy until relapse 3.1 months. Of the relapsed patients, 22/28 (79%) achieved CR regardless of the type of prior intensive maintenance (HD Ara-C/m-AMSA/5-azacytidine) (AZA) or daunorubicin (DNR/CD-Ara-C). Three of the 28 (11%) patients died during hypoplasia; 3/28 (11%) were refractory to 2x ID-Ara-C/m-AMSA. Three of the 28 patients died in CR during hypoplasia after intensive consolidation with HD-Ara-C. Predictive factors for remission were duration of preceding remission and the time from last chemotherapy to relapse. Three patients were transplanted in second CR. One of the six refractory patients reached CR, two remained refractory, and three died during hypoplasia. The median duration of disease-free survival (DFS) of relapsed patients was 3.3 months without further treatment; median survival of responding patients (20 relapsed patients, 1 refractory patient) was 4.5 months, overall survival (n = 29) was 4.8 months. Patients receiving BMT were censored at the time of BMT. Seven patients experienced lung toxicity due to Ara-C, four of whom died.(ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"333-8"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12855813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Update of the cytogenetic study of childhood non-high-risk acute lymphocytic leukemia at diagnosis in protocol VI of the Dutch Childhood Leukemia Study Group. 荷兰儿童白血病研究组方案六诊断儿童非高危急性淋巴细胞白血病细胞遗传学研究的最新进展。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_33

R M Slater, D F Smeets, A Hagemeijer, B De Jong, C G Beverstock, J P Geraedts, A van der Does-van den Berg, E R van Wering, A J Veerman

引用次数: 5

Acute promyelocytic leukemia: clinical findings and therapeutic results in 30 patients. 急性早幼粒细胞白血病30例临床分析及治疗效果。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_66

V Runde, C Aul, H Landen, A Dokekias, G Fillet, W Schneider

引用次数: 4

In vitro growth kinetics of myeloid progenitor cells of myelodysplastic patients in response to granulocyte-macrophage colony-stimulating factor and interleukin-3. 粒细胞-巨噬细胞集落刺激因子和白细胞介素-3对骨髓增生异常患者骨髓祖细胞体外生长动力学的影响

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_18

M R Schipperus, N Vink, J Lindemans, A Hagemeijer, P Sonneveld, J Abels

引用次数: 3

Management of fungal infection in neutropenic patients with fluconazole. 中性粒细胞减少患者真菌感染的氟康唑治疗。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_97

K W Brammer

{"title":"Management of fungal infection in neutropenic patients with fluconazole.","authors":"K W Brammer","doi":"10.1007/978-3-642-74643-7_97","DOIUrl":"https://doi.org/10.1007/978-3-642-74643-7_97","url":null,"abstract":"Fluconazole is a new orally absorbed antifungal azole which is effective in the treatment of mucosal and systemic infections caused by Candida, cryptococci and other fungi. In view of its favourable efficacy, safety and pharmacokinetic profile it was considered appropriate to evaluate its use prophylactically in patients undergoing a period of neutropenia. Two hundred and forty-eight patients receiving chemotherapy and/or bone marrow transplantation for the treatment of acute leukaemia, lymphoma or aplastic anaemia, and expected to be rendered temporarily neutropenic, have been entered into an ongoing multicentre comparative clinical study to compare the prophylactic efficacy of 50 mg daily oral fluconazole with that of widely used regimens of oral polyenes. The incidence of suspected fungal infection was less in the fluconazole group (27%) than in the polyene group (45%), the difference being statistically significant (P less than 0.05). Only one of the suspected infections in the fluconazole group was confirmed mycologically compared with 17 in the polyene group. Fluconazole prophylaxis was well tolerated and it therefore offers a promising new approach to the management of fungal infection in the neutropenic patient. Further studies are warranted to define the optimum dosage for use in this situation.","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"546-50"},"PeriodicalIF":0.0,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-3-642-74643-7_97","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13335238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 38

Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial. 维拉帕米对蒽环类药物引起的心肌病的影响:一项前瞻性多中心试验的初步结果。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_103

J Kraft, W Grille, M Appelt, D K Hossfeld, M Eichelbaum, B Koslowski, K Quabeck, R Kuse, T Büchner, W Hiddemann

引用次数: 14

Lymphokine-activated killer (LAK) cells against human leukemia: augmentation of LAK-cell cytotoxicity by combinations of lymphokines or cytokines. 淋巴因子激活的杀伤细胞(LAK)对抗人类白血病:通过淋巴因子或细胞因子的组合增强LAK细胞的细胞毒性。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_19

J V Teichmann, W D Ludwig, H Seibt-Jung, E Thiel

引用次数: 1

Therapy of childhood acute nonlymphocytic leukemia: the Pediatric Oncology Group experience (1977-1988). 儿童急性非淋巴细胞白血病的治疗:儿科肿瘤学组的经验(1977-1988)。

Haematology and blood transfusion Pub Date : 1990-01-01 DOI: 10.1007/978-3-642-74643-7_37

C P Steuber, S J Culbert, Y Ravindranath, J Krischer, A Ragab, C Civin, S Inoue, F Ruymann, B Leventhal, R Wilkinson

引用次数: 10